Cyclerion Therapeutics Receives Positive FDA Feedback for CYC-126 Phase 2 TRD Study and Forms Clinical Advisory Board

summarizeSummary

Cyclerion Therapeutics received positive FDA feedback for its lead product candidate, CYC-126, in Treatment Resistant Depression, providing clarity on its Phase 2 study and regulatory path. The company also formed a Clinical Advisory Board, reinforcing its development efforts and keeping it on track for a key clinical trial initiation.

check_boxKey Events

• Positive FDA Feedback for CYC-126

  Cyclerion Therapeutics received positive written feedback from the FDA regarding the Phase 2 proof-of-concept study for CYC-126 in Treatment Resistant Depression (TRD), providing clarity on its regulatory jurisdiction and development pathway.

• Phase 2 Study On Track

  The FDA feedback supports the planned Phase 2 study design, allowing the company to remain on track to initiate the study in the second half of 2026, with U.S. enrollment commencing in the first half of 2027.

• Clinical Advisory Board Formed

  The company announced the formation of a Clinical Advisory Board (CAB) comprising five internationally recognized leaders in neuropsychiatry, anesthesiology, and clinical development to provide strategic guidance for CYC-126.

auto_awesomeAnalysis

Cyclerion Therapeutics, a biopharmaceutical company, announced positive written feedback from the FDA regarding the Phase 2 proof-of-concept study for its lead product candidate, CYC-126, in Treatment Resistant Depression (TRD). This feedback provides crucial clarity on the regulatory pathway and supports the planned study design, significantly de-risking the development process for this micro-cap company's primary asset. The formation of a Clinical Advisory Board with recognized experts further strengthens the program's credibility and strategic guidance. This progress keeps the company on track to initiate the Phase 2 study in the second half of 2026, which is a critical milestone for its future.